Clinical Trial Update: A Study to Evaluate PT-523 in Patients With Refractory Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating PT-523 in patients with refractory leukemia (Phase 1/Phase 2) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• PT-523

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN